Key result
Fenofibrate produced greater reductions in total cholesterol, LDL, and triglycerides, and greater increases in HDL compared with gemfibrozil.
Why the study?
Does switching to fenofibrate improve lipid profiles compared to gemfibrozil in patients with dyslipidemic coronary heart disease?
Does switching to fenofibrate improve lipid profiles compared to gemfibrozil in patients with dyslipidemic coronary heart disease?
In patients with dyslipidemic coronary heart disease, switching from gemfibrozil to fenofibrate significantly improves lipid profiles, including those on concomitant statin therapy.
Answers are grounded in this paper and cite their sources.
May support fenofibrate preference for lipid improvement in dyslipidemic CHD; leaves open outcome confirmation in randomized trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Packard et al. (2002) studied Dyslipidemic coronary heart disease (n=80). Fenofibrate vs. Gemfibrozil was evaluated on Reductions in total cholesterol, LDL, and triglycerides (p=<0.001). Fenofibrate produced greater reductions in total cholesterol, LDL, and triglycerides, and greater increases in HDL compared with gemfibrozil.
Synapse has enriched 10 related papers. Consider them for comparative context: